Expert opinion on drug delivery最新文献

Treating glioblastoma with dextrin-based polymers. 用糊精基聚合物治疗胶质母细胞瘤。

IF 5.4

Expert opinion on drug delivery Pub Date : 2025-10-09 DOI: 10.1080/17425247.2025.2570845

Chiara Bastiancich, Chiara Molinar, Aurélie Tchoghandjian, Roberta Cavalli, Anna Scomparin

{"title":"Treating glioblastoma with dextrin-based polymers.","authors":"Chiara Bastiancich, Chiara Molinar, Aurélie Tchoghandjian, Roberta Cavalli, Anna Scomparin","doi":"10.1080/17425247.2025.2570845","DOIUrl":"10.1080/17425247.2025.2570845","url":null,"abstract":"Introduction: Dextrins are biodegradable, highly soluble, natural derivatives of starch, which occur in two main forms, either as linear polymers or as cyclic oligosaccharides, commonly known as cyclodextrins. The two structures present favorable features to be exploited in the development of drug delivery systems.Areas covered: This review explores dextrin- and cyclodextrin-based polymeric systems as innovative platforms for drug delivery in the treatment of glioblastoma, one of the most aggressive and lethal brain tumors. Despite advances in oncology, glioblastoma remains largely incurable due to the absence of effective therapeutic protocols. Consequently, novel strategies are being investigated, including both local and systemic administration of chemotherapeutic and targeted agents. Cyclodextrins, in particular, show promise as drug carriers owing to their ability to interact with the blood - brain barrier and enhance drug permeation. We summarize key preclinical studies employing cyclodextrin-based systems to deliver diverse anticancer agents, including cytotoxic drugs, immunotherapies, oligonucleotides, and antioxidants. Special emphasis is placed on unmet clinical needs, the challenges of experimental models, and the advantages offered by cyclodextrin formulations in glioblastoma therapy.Expert opinion: Albeit far from clinical application, cyclodextrin-based polymers hold a strong potential as innovative treatment against glioblastoma.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1-21"},"PeriodicalIF":5.4,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145214666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Future outcomes and current limitations of injectable implants for vocal fold scarring. 注射植入物治疗声带瘢痕的未来结果和当前局限性。

IF 5.4

Expert opinion on drug delivery Pub Date : 2025-10-07 DOI: 10.1080/17425247.2025.2569640

Nour Awad, Denzel Ryan D Cruz, Luigi Melaragno, Sapir Pinhas, Peter J Larson, Gregory R Dion

{"title":"Future outcomes and current limitations of injectable implants for vocal fold scarring.","authors":"Nour Awad, Denzel Ryan D Cruz, Luigi Melaragno, Sapir Pinhas, Peter J Larson, Gregory R Dion","doi":"10.1080/17425247.2025.2569640","DOIUrl":"10.1080/17425247.2025.2569640","url":null,"abstract":"Introduction: Vocal fold (VF) scarring poses a significant challenge. It is characterized by prolonged and often irreversible impairment of vocal function due to loss of pliability and disruption of the lamina propria's native extracellular matrix. Current treatments remain largely palliative, aiming to improve glottic closure rather than restore normal tissue biomechanics. As research deepens into the wound healing pathways and fibrotic mechanisms underlying scar formation, injectable therapies are emerging as approaches to modulate healing and restore vibratory function.Areas covered: This review outlines the pathophysiology of VF scarring and evaluates emerging injectable strategies designed to restore tissue architecture and function. These include biomaterial-based implants, antifibrotic and pro-regenerative biologics, stem cell therapies, and advanced drug delivery systems. The translational challenges include anatomical constraints, delivery precision, animal models, immune compatibility, degradation kinetics, and the lack of standardized outcome measures.Expert opinion: The review highlights the ongoing research on injections of implants for VF scarring that support biomechanical properties and modulate local tissue repair. However, further advanced and long-term studies, including clinical trials, are needed to fully elucidate their safety, efficacy, and toxicity profiles. In addition, their scalability and reproducibility within pharmaceutical manufacturing must be rigorously validated to support clinical translation.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1-20"},"PeriodicalIF":5.4,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145208654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biomimetic nanocarriers for targeted therapy of colorectal cancer. 用于结直肠癌靶向治疗的仿生纳米载体。

IF 5.4

Expert opinion on drug delivery Pub Date : 2025-10-03 DOI: 10.1080/17425247.2025.2570847

Shivam Pathak, Rupam Bera, Anjana Sharma, Dipti Kakkar, Balak Das Kurmi, Pradhi Srivasatava, Maitrayee Ghosh, Nitin Sharma

{"title":"Biomimetic nanocarriers for targeted therapy of colorectal cancer.","authors":"Shivam Pathak, Rupam Bera, Anjana Sharma, Dipti Kakkar, Balak Das Kurmi, Pradhi Srivasatava, Maitrayee Ghosh, Nitin Sharma","doi":"10.1080/17425247.2025.2570847","DOIUrl":"https://doi.org/10.1080/17425247.2025.2570847","url":null,"abstract":"Introduction: Colorectal cancer remains one of the most prevalent and lethal malignancies worldwide, with treatment often hampered by poor drug bioavailability, systemic toxicity, and resistance to conventional therapies. Biomimetic nanocarriers have emerged as a promising strategy to overcome these limitations by combining nanotechnology with the biological functions of cell-derived membranes.Areas covered: This review critically examines the design, fabrication, and application of biomimetic nanocarriers specifically for Colorectal cancer. Focusing on various membrane coatings, including red blood cells, platelets and cancer cells, and their role in enhancing drug delivery efficacy. It further explores the application of these nanocarriers in chemotherapy, immunotherapy, gene therapy, photothermal therapy, and cancer theranostics, while also discussing advances in targeting the unique tumor microenvironment of Colorectal cancer.Literature was retrieved from PubMed, Scopus, Web of Science and Google scholar databases covering publications from 2012 to May 2025.Expert opinion: Despite encouraging preclinical results, the clinical translation of biomimetic nanocarriers faces challenges including scalability, membrane heterogeneity, immunogenicity, and regulatory hurdles. Furthermore, existing studies often overlook the unique features of the Colorectal cancer tumor microenvironment. Future research should focus on precision nanomedicine tailored to Colorectal cancer, addressing current limitations to enable safer, more effective, and targeted cancer management.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145214637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Drug and stem cells delivery to salivary glands - a concise review. 唾液腺的药物和干细胞递送-简要回顾。

IF 5.4

Expert opinion on drug delivery Pub Date : 2025-10-03 DOI: 10.1080/17425247.2025.2569641

Janaki Iyer, Arvind Hariharan, Riho Kanai, Yuanyuan Peng, Mohammed Badwelan, Yoshinori Sumita, Simon D Tran

{"title":"Drug and stem cells delivery to salivary glands - a concise review.","authors":"Janaki Iyer, Arvind Hariharan, Riho Kanai, Yuanyuan Peng, Mohammed Badwelan, Yoshinori Sumita, Simon D Tran","doi":"10.1080/17425247.2025.2569641","DOIUrl":"https://doi.org/10.1080/17425247.2025.2569641","url":null,"abstract":"Introduction: Systemic equilibrium, oral health, and digestion depend on the health of the salivary glands (SGs). SG disorders, such as Sjögren's syndrome, oral and maxillofacial cancer, and radiation-induced damage, are usually associated with xerostomia, which severely impacts the patient's quality of life. Current therapeutic modalities primarily provide symptomatic therapy without addressing the basic underlying tissue damage or promoting regeneration. Emerging pharmacological and stem cell treatments may restore SG function, but tailored delivery, effectiveness, and safety issues restrict their clinical application.Areas covered: This review summarizes preclinical and clinical findings on systemic and localized stem cell and pharmaceutical drug administration. We discuss various SG conditions to match therapy methods to disease-specific demands and underline the necessity for accurate, efficient delivery systems to improve results and reduce adverse effects. We conclude with existing limits, future views, and prospective SG medicine regenerative therapy advancements.Expert opinion: Advancements in drug and stem cell delivery systems for SGs offer the potential to move beyond symptomatic relief and instead regenerate damaged tissues. These approaches promise more targeted, cost-effective, and long-lasting therapies, though challenges like immune rejection, safety, and cost remain significant. Future research should focus on improving stem cell sources, delivery, and tracking, while integrating technologies such as gene editing, nanocarriers, and tissue engineering to enhance efficacy. Ultimately, treatment strategies are shifting toward regenerative solutions aimed at restoring SG function with fewer systemic side effects.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145214664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advanced nano-delivery systems in H. pylori eradication: targeting, efficacy, and clinical translation. 幽门螺杆菌根除的先进纳米递送系统：靶向，疗效和临床翻译。

IF 5.4

Expert opinion on drug delivery Pub Date : 2025-10-03 DOI: 10.1080/17425247.2025.2569642

Tehsin Ullah Khan, Mohamed Sharaf, Sohaib Khan, Khurshid Ahmed, Chen-Guang Liu

{"title":"Advanced nano-delivery systems in H. pylori eradication: targeting, efficacy, and clinical translation.","authors":"Tehsin Ullah Khan, Mohamed Sharaf, Sohaib Khan, Khurshid Ahmed, Chen-Guang Liu","doi":"10.1080/17425247.2025.2569642","DOIUrl":"https://doi.org/10.1080/17425247.2025.2569642","url":null,"abstract":"Introduction: Helicobacter pylori infections demand innovative therapeutic strategies due to rising antibiotic resistance. This review consolidates recent advances in nanoparticle (NP)-based drug delivery systems engineered to optimize antimicrobial efficacy against H. pylori.Areas covered: We critically examine the design, functionality, and performance of metallic, polymeric, lipid-based, and biomimetic nano-carriers, highlighting their advantages over conventional antibiotic delivery.Expert opinion: Key innovations include: Lipid-based systems enabling synergistic co-delivery of hesperidin (0.064 μg mL⁻¹) and clarithromycin (0.15 mg mL⁻¹) for enhanced drug bioavailability; Polymeric NPs (e.g. rhamnolipid-chitosan hybrids) achieving deep biofilm penetration ( > 99% eradication) within gastric mucus at minimal inhibitory concentrations (32-132 µg/mL). These nanoplatforms demonstrate precision gastric-mucosa targeting, improved penetration of biological barriers, and controlled antimicrobial release. By maximizing localized drug delivery while minimizing systemic exposure, NP-based systems address critical limitations of current therapies, including resistance and microbiota disruption. We further emphasize the need for clinical validation to translate these delivery technologies into standardized treatments, ultimately reducing the global burden of H. pylori-associated diseases.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145214983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Attenuating amygdalin (vitamin B17) toxicity for potential therapeutic uses: insights into controlled release technology-based formulations as a strategy for improving clinical safety. 减轻苦杏仁苷（维生素B17）毒性的潜在治疗用途：洞察控释技术为基础的配方，以提高临床安全性的策略。

IF 5.4

Expert opinion on drug delivery Pub Date : 2025-10-02 DOI: 10.1080/17425247.2025.2570401

Zubair Khalid Baig Moghal, Rajesh Sreedharan Nair, Saghir Akhtar, Nashiru Billa

{"title":"Attenuating amygdalin (vitamin B17) toxicity for potential therapeutic uses: insights into controlled release technology-based formulations as a strategy for improving clinical safety.","authors":"Zubair Khalid Baig Moghal, Rajesh Sreedharan Nair, Saghir Akhtar, Nashiru Billa","doi":"10.1080/17425247.2025.2570401","DOIUrl":"https://doi.org/10.1080/17425247.2025.2570401","url":null,"abstract":"Introduction: Amygdalin, is arguably, one of the most controversial molecules found in nature, with several therapeutic properties, including anticancer, but there are concerns over its toxicity on healthy tissue alike, which warrants a modified approach toward its utilization in therapy.Areas covered: This review examines a rational approach toward its effective deployment in managing several diseases, anticancer, and anti-fibrotic, anti-inflammatory effects. The search for relevant articles was conducted by scouting the PubMed and Scopus on published articles from 2014-2025. We capture the key modulatory pathways of amygdalin that conveys several of its therapeutic effects and paradoxically, the observed toxicity in healthy tissue. The review contends that amygdalin remains as a formidable therapeutic contender for treating several diseases, if the dose can be attenuated through controlled release from nanotechnological-based formulation.Expert opinion: Toxicity concerns and stability associated with amygdalin is best addressed through slow and controlled release from nano-encapsulation delivery systems. A further frontier can involve co or trio- nano-encapsulation of amygdalin with other therapeutic agents, whereby toxicity concerns and drug resistance are simultaneously addressed.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145208673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Differential targeting of olfactory epithelium and respiratory epithelium in nose-to-brain drug delivery. 嗅觉上皮和呼吸上皮在鼻-脑药物传递中的不同靶向性。

IF 5.4

Expert opinion on drug delivery Pub Date : 2025-10-02 DOI: 10.1080/17425247.2025.2568093

Anisha A D'Souza, Valentina DiFrancesco, Alicia Yang, Benjamin S Bleier, Mansoor M Amiji

{"title":"Differential targeting of olfactory epithelium and respiratory epithelium in nose-to-brain drug delivery.","authors":"Anisha A D'Souza, Valentina DiFrancesco, Alicia Yang, Benjamin S Bleier, Mansoor M Amiji","doi":"10.1080/17425247.2025.2568093","DOIUrl":"10.1080/17425247.2025.2568093","url":null,"abstract":"Introduction: Nose-to-brain drug delivery provides a promising noninvasive route to bypass the blood-brain barrier through direct nasal cavity-brain connections. Therapeutic agents reach the central nervous system via systemic circulation or olfactory/trigeminal nerve pathways. Only the olfactory epithelium enables direct brain transport through olfactory neurons, bypassing the blood-brain barrier, while the respiratory epithelium primarily supports systemic absorption before CNS access via trigeminal nerves.Areas covered: This review examines anatomical and functional differences between olfactory and respiratory epithelia, focusing on receptor, lectin, microbial, and enzymatic expression variations, particularly species-specific differences. These distinctions create opportunities for selective olfactory epithelium targeting. Key studies using formulation strategies and physical delivery methods to enhance olfactory-specific drug delivery are discussed, alongside analytical techniques for assessing olfactory accumulation. A systematic literature search across major databases through June 2025 supports these findings.Expert opinion: Despite decades of research, nose-to-brain drug delivery faces unresolved challenges. Major limitations include imprecise targeting of the olfactory epithelium and the lack of standardized in vitro and in vivo models for determining exact transport mechanisms and enabling cross-comparisons. Addressing these gaps is essential for advancing targeted nose-to-brain drug delivery systems.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1-20"},"PeriodicalIF":5.4,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145188189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Can nanoparticle-based intranasal delivery systems revolutionize treatment of central nervous system diseases? 基于纳米颗粒的鼻内给药系统能彻底改变中枢神经系统疾病的治疗吗？

IF 5.4

Expert opinion on drug delivery Pub Date : 2025-10-02 DOI: 10.1080/17425247.2025.2569644

Giuseppe Nunziata, Fabio Pizzetti, Pietro Veglianese, Gianluigi Forloni, Claudia Balducci, Filippo Rossi

引用次数: 0

Navigating the therapeutic landscape in advanced Parkinson's disease: a comprehensive review from infusion therapies to stem cells. 导航晚期帕金森病的治疗前景：从输注疗法到干细胞的全面回顾。

IF 5.4

Expert opinion on drug delivery Pub Date : 2025-10-01 Epub Date: 2025-08-01 DOI: 10.1080/17425247.2025.2539962

Carmelo Fogliano, Leonardo Rigon, K Ray Chaudhuri, Karolina Popławska-Domaszewicz, Cristian Falup-Pecurariu, Iulia Murasan, Andrea Guerra, Michela Garon, Per Odin, Nobutaka Hattori, Angelo Antonini

{"title":"Navigating the therapeutic landscape in advanced Parkinson's disease: a comprehensive review from infusion therapies to stem cells.","authors":"Carmelo Fogliano, Leonardo Rigon, K Ray Chaudhuri, Karolina Popławska-Domaszewicz, Cristian Falup-Pecurariu, Iulia Murasan, Andrea Guerra, Michela Garon, Per Odin, Nobutaka Hattori, Angelo Antonini","doi":"10.1080/17425247.2025.2539962","DOIUrl":"10.1080/17425247.2025.2539962","url":null,"abstract":"Introduction: Oral dopaminergic treatment is the cornerstone of Parkinson's disease (PD) management. However, progressive shortening of oral levodopa's effect, along with the limited efficacy of enzyme inhibitors and dopamine agonists, does not allow to adequately control motor and non-motor complications characterizing advanced PD. At this stage, device-aided therapies (DATs), including infusion treatments, are warranted to guarantee an adequate quality of life.Areas covered: We review current and upcoming infusion therapies for PD, with a particular focus on their efficacy and safety data. Moreover, we provide an overview of current knowledge and open issues on patient selection and specific DAT choice.Expert opinion: Recent EAN/MDS-ES guidelines suggest infusion therapies for advanced PD, yet several challenges remain, including limited access, delayed referrals, and patients' hesitancy. The '5-2-1' criteria and tools like MANAGE-PD aid early identification of eligible candidates, but treatment decisions often do not account for patients' preferences. Current trends favor early DATs implementation, as soon as motor fluctuations appear and before the disability onset. Emerging infusion therapies (e.g. foslevodopa-foscarbidopa) will boost this tendency. Enhancing DATs accessibility and inclusivity in clinical trials are key priorities. Finally, regenerative therapies including putaminal infusion of neurotrophic factors and dopaminergic neuron precursors may transform advanced PD care.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1599-1616"},"PeriodicalIF":5.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144746637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

3D printed hollow microneedles: the latest innovation in drug delivery. 3D打印空心微针：给药领域的最新创新。

IF 5.4

Expert opinion on drug delivery Pub Date : 2025-10-01 Epub Date: 2025-08-12 DOI: 10.1080/17425247.2025.2531062

Mahmood Razzaghi, Mohsen Akbari

{"title":"3D printed hollow microneedles: the latest innovation in drug delivery.","authors":"Mahmood Razzaghi, Mohsen Akbari","doi":"10.1080/17425247.2025.2531062","DOIUrl":"10.1080/17425247.2025.2531062","url":null,"abstract":"Introduction: Hollow microneedles (HMNs) offer a minimally invasive and highly efficient method for transdermal drug administration, overcoming the limitations of traditional delivery systems.Areas covered: This review focuses on recent advancements in 3D-printed HMNs, highlighting their transformative potential in drug delivery applications. The integration of cutting-edge 3D printing technologies, such as stereolithography (SLA), digital light processing (DLP), and two-photon polymerization (2PP), has enabled the fabrication of complex, precise, and customizable microneedles (MNs). These innovations facilitate patient-specific applications, enhance drug bioavailability, and provide unparalleled control over dosage and delivery. Advances in biocompatible and biodegradable materials have further improved the safety and functionality of HMNs. Applications range from insulin delivery to biomarker sensing and theranostic systems, showcasing their versatility.Expert opinion: 3D-printed HMNs are set to play an important role in improving personalized medicine and precision healthcare. By addressing fabrication and design issues, and using new materials, these devices are expected to change drug delivery systems and help develop new therapeutic and diagnostic platforms.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1487-1507"},"PeriodicalIF":5.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144568174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0